RT Journal Article
SR Electronic
T1 The RNA-binding profile of the splicing factor SRSF6 in immortalized human pancreatic β-cells
JF Life Science Alliance
JO Life Sci. Alliance
FD Life Science Alliance LLC
SP e202000825
DO 10.26508/lsa.202000825
VO 4
IS 3
A1 Alvelos, Maria Inês
A1 Brüggemann, Mirko
A1 Sutandy, FX Reymond
A1 Juan-Mateu, Jonàs
A1 Colli, Maikel Luis
A1 Busch, Anke
A1 Lopes, Miguel
A1 Castela, Ângela
A1 Aartsma-Rus, Annemieke
A1 König, Julian
A1 Zarnack, Kathi
A1 Eizirik, Décio L
YR 2021
UL http://www.life-science-alliance.org/content/4/3/e202000825.abstract
AB In pancreatic β-cells, the expression of the splicing factor SRSF6 is regulated by GLIS3, a transcription factor encoded by a diabetes susceptibility gene. SRSF6 down-regulation promotes β-cell demise through splicing dysregulation of central genes for β-cells function and survival, but how RNAs are targeted by SRSF6 remains poorly understood. Here, we define the SRSF6 binding landscape in the human pancreatic β-cell line EndoC-βH1 by integrating individual-nucleotide resolution UV cross-linking and immunoprecipitation (iCLIP) under basal conditions with RNA sequencing after SRSF6 knockdown. We detect thousands of SRSF6 bindings sites in coding sequences. Motif analyses suggest that SRSF6 specifically recognizes a purine-rich consensus motif consisting of GAA triplets and that the number of contiguous GAA triplets correlates with increasing binding site strength. The SRSF6 positioning determines the splicing fate. In line with its role in β-cell function, we identify SRSF6 binding sites on regulated exons in several diabetes susceptibility genes. In a proof-of-principle, the splicing of the susceptibility gene LMO7 is modulated by antisense oligonucleotides. Our present study unveils the splicing regulatory landscape of SRSF6 in immortalized human pancreatic β-cells.